Fluoroquinolone Antibiotics Exhibit Low Antiviral Activity against SARS-CoV-2 and MERS-CoV

Fluoroquinolone Antibiotics Exhibit Low Antiviral Activity against SARS-CoV-2 and MERS-CoV

Repurposing FDA-approved drugs that treat respiratory infections caused by coronaviruses, such as SARS-CoV-2 and MERS-CoV, could quickly provide much needed antiviral therapies. In the current study, the potency and cellular toxicity of four fluoroquinolones (enoxacin, ciprofloxacin, levofloxacin, a...

Full description

Bibliographic Details
Main Authors: Stacey L. P. Scroggs, Danielle K. Offerdahl, Dylan P. Flather, Ciera N. Morris, Benjamin L. Kendall, Rebecca M. Broeckel, Paul A. Beare, Marshall E. Bloom
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Viruses
Subjects:
SARS-CoV-2
Covid-19
MERS
fluoroquinolones
antiviral
efficacy
Online Access:https://www.mdpi.com/1999-4915/13/1/8

Internet

https://www.mdpi.com/1999-4915/13/1/8

Similar Items